{"id":2143,"date":"2011-12-14T00:00:00","date_gmt":"2011-12-14T08:00:00","guid":{"rendered":"https:\/\/vermont.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/"},"modified":"2023-12-11T14:02:46","modified_gmt":"2023-12-11T22:02:46","slug":"alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/es\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/","title":{"rendered":"Un f\u00e1rmaco candidato contra el Alzheimer podr\u00eda ser el primero en prevenir el avance de la enfermedad"},"content":{"rendered":"<p>LA JOLLA, CA\u2014Un nuevo candidato a f\u00e1rmaco podr\u00eda ser el primero capaz de detener el devastador deterioro mental de la enfermedad de Alzheimer, seg\u00fan los hallazgos de un estudio publicado en <em>PLoS ONE<\/em>.\r\n<\/p><p>\r\nCuando se administr\u00f3 a ratones con Alzheimer, el f\u00e1rmaco, conocido como J147, mejor\u00f3 la memoria y previno el da\u00f1o cerebral causado por la enfermedad. El nuevo compuesto, desarrollado por cient\u00edficos del Salk Institute for Biological Studies, podr\u00eda ser probado para el tratamiento de la enfermedad en humanos en un futuro cercano.\r\n<\/p><iframe src=\"https:\/\/www.youtube.com\/embed\/xz_0zujJjD0?rel=0\" frameborder=\"0\" allowfullscreen><\/iframe><p>\r\n\"J147 mejora la memoria tanto en ratones normales como en ratones con Alzheimer y tambi\u00e9n protege al cerebro de la p\u00e9rdida de conexiones sin\u00e1pticas\", dice <a href=\"\/es\/faculty\/schubert.html\/\">David Schubert<\/a>, director del Laboratorio de Neurobiolog\u00eda Celular de Salk, cuyo equipo desarroll\u00f3 el nuevo f\u00e1rmaco. \"Ning\u00fan f\u00e1rmaco en el mercado para el alzh\u00e9imer tiene ambas propiedades\".\"\r\n<\/p><p>\r\nAunque a\u00fan se desconoce si el compuesto resultar\u00e1 seguro y eficaz en humanos, los investigadores del Salk dicen que sus resultados sugieren que el f\u00e1rmaco podr\u00eda tener potencial para el tratamiento de personas con Alzheimer.\r\n<\/p><p>\r\nSeg\u00fan los Institutos Nacionales de Salud, hasta 5.4 millones de estadounidenses sufren de Alzheimer. M\u00e1s de 16 millones tendr\u00e1n la enfermedad para 2050, seg\u00fan <a href=\"http:\/\/www.alz.org\">Asociaci\u00f3n de Alzheimer<\/a> estimaciones, lo que resulta en costos m\u00e9dicos de m\u00e1s de $1 bill\u00f3n por a\u00f1o.\r\n<\/p><div class=\"imageCaption\"><img decoding=\"async\" src=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2011\/01\/532-schubert.jpg\" alt=\"J147\" width=\"300\"><p>Cient\u00edficos de Salk desarrollan J147, una droga sint\u00e9tica que mejora la memoria y previene el da\u00f1o cerebral en ratones con enfermedad de Alzheimer. <\/p><p>Imagen: Cortes\u00eda del Instituto Salk de Estudios Biol\u00f3gicos<\/p><\/div>\r\n<p>\r\nLa enfermedad causa un declive constante e irreversible en la funci\u00f3n cerebral, borrando la memoria de una persona y su capacidad para pensar con claridad hasta que ya no puede realizar tareas simples como comer y hablar, y finalmente es fatal. El Alzheimer est\u00e1 relacionado con el envejecimiento y generalmente aparece despu\u00e9s de los 60 a\u00f1os, aunque un peque\u00f1o porcentaje de familias tiene un riesgo gen\u00e9tico de aparici\u00f3n m\u00e1s temprana. Entre las diez principales causas de muerte, el Alzheimer es la \u00fanica sin una forma de prevenir, curar o ralentizar la progresi\u00f3n de la enfermedad.\r\n<\/p><p>\r\nLos cient\u00edficos no tienen claro qu\u00e9 causa el Alzheimer, que parece surgir de una compleja mezcla de factores gen\u00e9ticos, ambientales y de estilo de vida. Hasta ahora, los medicamentos desarrollados para tratar la enfermedad, como Aricept, Razadyne y Exelon, solo producen mejoras ef\u00edmeras de la memoria y no hacen nada para frenar el curso general de la enfermedad.\r\n<\/p><p>\r\nPara encontrar un nuevo tipo de f\u00e1rmaco, Schubert y sus colegas se desviaron de la tendencia dentro de la industria farmac\u00e9utica de centrarse exclusivamente en las v\u00edas biol\u00f3gicas involucradas en la formaci\u00f3n de las placas amiloides, los dep\u00f3sitos densos de prote\u00edna que caracterizan la enfermedad. Hasta la fecha, dice Schubert, todos los f\u00e1rmacos basados en amiloide han fracasado en ensayos cl\u00ednicos.\r\n<\/p><p>\r\nEn cambio, el equipo de Salk desarroll\u00f3 m\u00e9todos para usar neuronas vivas cultivadas en placas de laboratorio para probar si nuevos compuestos sint\u00e9ticos eran efectivos para proteger las c\u00e9lulas cerebrales contra varias patolog\u00edas asociadas con el envejecimiento cerebral. Bas\u00e1ndose en los resultados de las pruebas de cada iteraci\u00f3n qu\u00edmica del compuesto principal, que originalmente se desarroll\u00f3 para el tratamiento de derrames cerebrales y lesiones cerebrales traum\u00e1ticas, pudieron alterar su estructura qu\u00edmica para crear un f\u00e1rmaco mucho m\u00e1s potente contra el Alzheimer.\r\n<\/p><p>\r\n\"El Alzheimer es una enfermedad compleja, pero la mayor parte del desarrollo de medicamentos en el mundo farmac\u00e9utico se ha enfocado en un solo aspecto de la enfermedad: la v\u00eda del amiloide\", dice Marguerite Prior, asociada de investigaci\u00f3n en el laboratorio de Schubert, quien dirigi\u00f3 el proyecto junto con Qi Chen, ex investigadora postdoctoral en Salk. \"Por el contrario, al probar estos compuestos en cultivos de c\u00e9lulas vivas, podemos determinar qu\u00e9 hacen contra una variedad de problemas relacionados con la edad y seleccionar el mejor candidato que aborde m\u00faltiples aspectos de la enfermedad, no solo uno\".\"\r\n<\/p><p>\r\nCon un compuesto prometedor en mano, los investigadores pasaron a probar el J147 como medicamento oral en ratones. Trabajando con Amanda Roberts, profesora de neurociencias moleculares en el Instituto de Investigaci\u00f3n Scripps, realizaron una serie de pruebas conductuales que demostraron que el f\u00e1rmaco mejoraba la memoria en roedores sanos.\r\n<\/p><p>\r\nLos investigadores de Salk demostraron adem\u00e1s que previno el deterioro cognitivo en animales con Alzheimer y que ratones y ratas tratados con el f\u00e1rmaco produjeron m\u00e1s de una prote\u00edna llamada factor neurotr\u00f3fico derivado del cerebro (BDNF), una mol\u00e9cula que protege las neuronas de da\u00f1os t\u00f3xicos, ayuda a que las nuevas neuronas crezcan y se conecten con otras c\u00e9lulas cerebrales, y est\u00e1 involucrada en la formaci\u00f3n de la memoria.\r\n<\/p><p>\r\nDebido a la amplia capacidad de J147 para proteger las neuronas, los investigadores creen que tambi\u00e9n podr\u00eda ser eficaz para tratar otros trastornos neurol\u00f3gicos, como la enfermedad de Parkinson, la enfermedad de Huntington y la esclerosis lateral amiotr\u00f3fica (ELA), as\u00ed como el accidente cerebrovascular.            \r\n<\/p><p>\r\nLa investigaci\u00f3n fue financiada por la Fritz B. Burns Foundation, los National Institutes of Health, la Bundy Foundation y la Alzheimer's Association.\r\n<\/p><p><strong>\r\nAcerca del Instituto Salk de Estudios Biol\u00f3gicos:<\/strong><br \/>\r\nEl Instituto Salk de Estudios Biol\u00f3gicos es una de las instituciones de investigaci\u00f3n b\u00e1sica m\u00e1s importantes del mundo, donde el profesorado de renombre internacional investiga cuestiones fundamentales de las ciencias de la vida en un entorno \u00fanico, colaborativo y creativo. Centrados tanto en el descubrimiento como en la mentor\u00eda de futuras generaciones de investigadores, los cient\u00edficos de Salk realizan contribuciones revolucionarias a nuestra comprensi\u00f3n del c\u00e1ncer, el envejecimiento, el Alzheimer, la diabetes y las enfermedades infecciosas mediante el estudio de la neurociencia, la gen\u00e9tica, la biolog\u00eda celular y vegetal, y disciplinas relacionadas.\r\n<\/p><p>\r\nLos logros del cuerpo docente han sido reconocidos con numerosos galardones, entre los que se incluyen premios Nobel y la pertenencia a la Academia Nacional de Ciencias. Fundado en 1960 por el Dr. Jonas Salk, pionero en la vacuna contra la poliomielitis, el Instituto es una organizaci\u00f3n independiente sin fines de lucro y un hito arquitect\u00f3nico.<\/p>\r\n<p><strong>Para m\u00e1s informaci\u00f3n:<\/strong><br \/>\r\n<em>PLoS ONE<\/em><br \/>\r\nAutores: Qi Chen, Marguerite Prior, Richard Dargusch, Amanda Roberts, Roland Riek, Cedric Eichmann, Chandramouli Chiruta, Tatsuhiro Akaishi, Kazuho Abe, Pamela Maher, David Schubert<br \/>\r\n<a href=\"http:\/\/http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0027865\">Un novedoso f\u00e1rmaco neurotr\u00f3fico para la mejora cognitiva y la enfermedad de Alzheimer<\/a><\/p>","protected":false},"featured_media":0,"template":"","faculty":[113],"disease-research":[127,146,124,460],"class_list":["post-2143","disclosure","type-disclosure","status-publish","hentry","faculty-dave-schubert","disease-research-alzheimers-disease","disease-research-aging-and-regenerative-medicine","disease-research-neuroscience-and-neurological-disorders","disease-research-traumatic-brain-injury"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alzheimer&#039;s drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/es\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer&#039;s drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, CA\u2014A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer&#039;s disease, based on the findings of a study published in PLoS ONE.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/es\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-11T22:02:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"628\" \/>\n\t<meta property=\"og:image:height\" content=\"329\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/\",\"name\":\"Alzheimer's drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2011\\\/01\\\/532-schubert.jpg\",\"datePublished\":\"2011-12-14T08:00:00+00:00\",\"dateModified\":\"2023-12-11T22:02:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/#breadcrumb\"},\"inLanguage\":\"es-MX\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-MX\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2011\\\/01\\\/532-schubert.jpg\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2011\\\/01\\\/532-schubert.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzheimer&#8217;s drug candidate may be first to prevent disease progression\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-MX\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-MX\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzheimer's drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/es\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/","og_locale":"es_MX","og_type":"article","og_title":"Alzheimer's drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies","og_description":"LA JOLLA, CA\u2014A new drug candidate may be the first capable of halting the devastating mental decline of Alzheimer's disease, based on the findings of a study published in PLoS ONE.","og_url":"https:\/\/www.salk.edu\/es\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2023-12-11T22:02:46+00:00","og_image":[{"width":628,"height":329,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk-institute-preview-image.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/","url":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/","name":"Alzheimer's drug candidate may be first to prevent disease progression - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2011\/01\/532-schubert.jpg","datePublished":"2011-12-14T08:00:00+00:00","dateModified":"2023-12-11T22:02:46+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/#breadcrumb"},"inLanguage":"es-MX","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/"]}]},{"@type":"ImageObject","inLanguage":"es-MX","@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2011\/01\/532-schubert.jpg","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2011\/01\/532-schubert.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/alzheimers-drug-candidate-may-be-first-to-prevent-disease-progression\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"Alzheimer&#8217;s drug candidate may be first to prevent disease progression"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"Instituto Salk de Estudios Biol\u00f3gicos","description":"El Poder de la Ciencia","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-MX"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"Instituto Salk de Estudios Biol\u00f3gicos","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"es-MX","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"paper_url":"http:\/\/www.plosone.org\/article\/info%3Adoi%2F10.1371%2Fjournal.pone.0027865","journal_title":"PLOS ONE","paper_author_list":"Qi Chen, Marguerite Prior, Richard Dargusch, Amanda Roberts, Roland Riek, Cedric Eichmann, Chandramouli Chiruta, Tatsuhiro Akaishi, Kazuho Abe, Pamela Maher, David Schubert","paper_title":"A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer's Disease","subhead":"Salk scientists develop new drug that improves memory and prevents brain damage in mice","home_photo":"2011\/532-SchubertPriorHeadshot.jpg","listing_photo":"532.jpg","gallery":false,"legacy_boilerplate":[],"doi":"","hide_boilerplate":[],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false,"og_image_override":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/2143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":1,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/2143\/revisions"}],"predecessor-version":[{"id":45193,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disclosure\/2143\/revisions\/45193"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/media?parent=2143"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/faculty?post=2143"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/es\/wp-json\/wp\/v2\/disease-research?post=2143"}],"curies":[{"name":"la hora de","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}